Last reviewed · How we verify
nedaplatin and docetaxel
At a glance
| Generic name | nedaplatin and docetaxel |
|---|---|
| Also known as | TN |
| Sponsor | Guangxi Medical University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients (PHASE2)
- Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor (PHASE2)
- A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC (PHASE2)
- Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas (PHASE2)
- A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (PHASE2)
- Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer (PHASE2)
- Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC (PHASE3)
- Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nedaplatin and docetaxel CI brief — competitive landscape report
- nedaplatin and docetaxel updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI